NPC1L1 and coronary artery disorder: The Improved Reduction of Outcomes: Vytorin Efficacy International Trial has revealed that the addition of ezetimibe, a non-statin drug that inhibits the intestinal absorption of cholesterol by targeting Niemann-Pick C1-Like 1 (NPC1L1), to simvastatin resulted in the lowering of LDL cholesterol levels by approximately 24% and improved the outcome of the patients with coronary artery disease (62).